Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis

Journal of Investigative Dermatology

Volumn 126, Issue 2, 2006, Pages 453-459

  Young, Helen S ^a,b,d,e   Summers, Angela M ^b   Read, Ian R ^b   Fairhurst, David A ^a   Plant, Darren J ^a   Campalani, Emanuela ^c   Smith, Catherine H ^c   Barker, Jonathan N W N ^c   Detmar, Michael J ^d   Brenchley, Paul E C ^b   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; RETINOIC ACID; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CELL TYPE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSORIASIS; UNINDEXED SEQUENCE;

ACITRETIN; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; KERATINOCYTES; LEUKOCYTES, MONONUCLEAR; MALE; POLYMORPHISM, GENETIC; PSORIASIS; RETINOIDS; TRETINOIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644638611     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700096     Document Type: Article

References (36)

1. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al. (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-9
2. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-43
3. Barnhill RL, Parkinson EK, Ryan TJ (1984) Supernatants from cultured human epidermal keratinocytes stimulate angiogenesis. Br J Dermatol 110:273-81
4. Bhushan M, McLaughlin B, Weiss JB, Griffiths CEM (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054-60
5. Brenchley PEC (2000) Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 121:426-9
6. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245-9
7. Capon F, Trembath RC, Barker JNWN (2004) An update on the genetics of psoriasis. Dermatol Clin 22:339-47, vii
8. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker JNWN (2002) Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791-6
9. Creamer D, Allen MH, Groves RW, Barker JNWN (1996) Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 348:1101
10. Creamer D, Allen MH, Sousa A, Poston R, Barker JNWN (1997) Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136:859-65
11. Creamer JD, Barker JNWN (1995) Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 20:6-9
12. Detmar M (1996) Molecular regulation of angiogenesis in the skin. J Invest Dermatol 106:207-8
13. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW et al. (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-6
14. Detmar M, Yeo KT, Nagy JA, Van de WL, Brown LF, Berse B et al. (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44-50
15. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S (2000) Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 275:642-50
16. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-43
17. Fry L (1988) Psoriasis. Br J Dermatol 119:445-61
18. Gawkrodger DJ (1997) Current management of psoriasis. J Dermatolog Treat 8:27-55
19. Griffiths CEM, Camp RDR, Barker JNWN (2004) Psoriasis. In: Rook's textbook of dermatology. (Burns DA, Breathnach SM, Cox NH, Griffiths CEM, eds), 7th ed, Oxford: Blackwell Science
20. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC (2000) A systematic review of treatments for severe psoriasis. Monograph 4:1-124
21. Griffiths CEM, Voorhees JJ (1996) Psoriasis, T cells and autoimmunity. J R Soc Med 89:315-9
22. Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450-6
23. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-4
24. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P et al. (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104:1048-57
25. Lambrechts D, Storkebaum E, Morimoto M, Del Favero J, Desmet F, Marklund SL et al. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383-94
26. Malhotra R, Stenn KS, Fernandez LA, Braverman IM (1989) Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. Lab Invest 61:162-5
27. Mattei MG, Borg JP, Rosnet O, Marme D, Birnbaum D (1996) Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics 32:168-9
28. Peehl DM, Ham RG (1980) Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium. In Vitro 16:516-25
29. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443-8
30. Sambrook J, Pollack R (1974) Basic methodology for cell culture - cell transformation. Methods Enzymol 32:583-92
31. Summers AM, Coupes BM, Brennan MF, Ralph SA, Short CD, Brenchley PEC (2005) VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant 20:2427-32
32. Thomas KA (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271:603-6
33. Todd C, Reynolds NJ (1998) Up-regulation of p21WAF1 by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. Am J Pathol 153:39-45
34. Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493-5
35. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-5
36. Young HS, Summers AM, Bhushan M, Brenchley PEC, Griffiths CEM (2004) Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122:209-15